Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Tax Provisions (2022 - 2026)

Indivior Pharmaceuticals has reported Tax Provisions over the past 5 years, most recently at $26.0 million for Q1 2026.

  • For Q1 2026, Tax Provisions rose 136.36% year-over-year to $26.0 million; the TTM value through Mar 2026 reached $44.0 million, up 238.46%, while the annual FY2025 figure was $29.0 million, 123.08% up from the prior year.
  • Tax Provisions for Q1 2026 was $26.0 million at Indivior Pharmaceuticals, up from -$21.0 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $73.0 million in Q4 2022 and troughed at -$23.0 million in Q2 2023.
  • A 5-year average of $7.5 million and a median of $1.5 million in 2024 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: soared 453.85% in 2023 and later plummeted 223.53% in 2025.
  • Year by year, Tax Provisions stood at $73.0 million in 2022, then crashed by 109.59% to -$7.0 million in 2023, then soared by 342.86% to $17.0 million in 2024, then plummeted by 223.53% to -$21.0 million in 2025, then skyrocketed by 223.81% to $26.0 million in 2026.
  • Business Quant data shows Tax Provisions for INDV at $26.0 million in Q1 2026, -$21.0 million in Q4 2025, and -$5.0 million in Q3 2025.